aod9604 igf-1 levels study AOD 9604: Peptide Claims vs Clinical Reality AOD 9604 is marketed as a fat-metabolism peptide derived from a growth hormone fragment, often positioned as “HGH-like” without HGH's side effects. The clinical question AOD 9604 Peptide for Fat
Description
The preclinical data is generally consistent and encouraging
Bedtime dosing works well because sleep represents a natural fasted state
Because the peptide works specifically through beta-3 adrenergic receptors in adipose tissue and does not affect growth hormone receptors, IGF-1, or glucose metabolism, it does not create the compounding effects or interaction concerns associated with growth hormone therapy
Despite all good intentions, low energy usually means they never get anything out of it
Body composition measurements via DEXA scan or bioimpedance scale every 4-8 weeks
Let's start with the science
